Liquid Biopsy Market Dominated by Circulating Tumor DNA, Estimated at $4.01 Billion in 2023
The global liquid biopsy market size is estimated to be worth $5.4 billion in 2023 and is expected to grow at compounded annual growth rate (CAGR) of 15.2%, during the forecast period. The growth in the liquid biopsy market size over the next decade is likely to be driven by the rise in demand for non invasive liquid biopsy products due to growing focus on early cancer detection.
Cancer is the second leading cause of death globally, and the increasing global incidence of cancer is becoming a critical health challenge. According to WHO, approximately 16.3 million cancer related deaths are likely to occur by 2040. Among various cancer indications, breast cancer is the most common type of cancer worldwide, followed by lung cancer, colorectal cancer, and prostate cancer. According to the SEER statistics, nearly 18% women are expected to be diagnosed with breast cancer at some point during their lifetime, with an estimated 297,790 new cases in 2023. In order to address the growing cancer burden, numerous cancer research organizations are actively adopting innovative strategies and patient-centered approaches for early diagnosis and treatment of cancer.
Early cancer detection is an important element that may contribute in the overall success of cancer treatment and can increase the survival rate of patients with cancer. For many years, tissue biopsy has been considered the gold standard for cancer diagnosis. However, the limitations associated with this invasive procedure, such as discomfort, pain and risk of complications have hindered the wide acceptance of this technique for cancer diagnosis. Over time, extensive research on liquid biopsy has resulted in its recognition as a viable technique for cancer detection. The past decade has witnessed substantial innovation in liquid biopsy platforms that have resulted in increased regulatory approvals for minimally invasive blood based liquid biopsy tests. Liquid biopsy products offer a minimally invasive and accessible method for early cancer detection and patient monitoring. These tests use blood samples or other bodily fluids, such as urine or plasma to identify genetic mutations and various circulating biomarkers, including circulating tumor DNA, cell free DNA and extracellular vesicles. These non invasive tests are transforming cancer care, especially for patients with advanced cancer stages.
The liquid biopsy market is a dynamic, rapidly growing sector, with numerous companies investing heavily in research and development. These investments capitalize on scientific advancements in liquid biopsy industry, heralding a new era in cancer diagnostics within the oncology industry. With continuous innovation in this field, it is anticipated that the adoption of such liquid biopsy and other non invasive cancer diagnostics will increase significantly, driving the liquid biopsy market growth during the forecast period.
Key Market Insights
This market report features an extensive study of the current market landscape, market size, market forecast and future opportunities associated with the liquid biopsy companies involved in development of liquid biopsy and other non invasive cancer diagnostics, during the given forecast period. Further, the market report highlights the efforts of various stakeholders engaged in this rapidly emerging segment of the diagnostics industry. Key takeaways of the liquid biopsy market are briefly discussed below.
Growing Demand for Liquid Biopsy and Other Non Invasive Cancer Diagnostics
Given the numerous advantages, there is a growing demand for liquid biopsy and other non invasive cancer diagnostics, particularly in early cancer detection, patient monitoring, and treatment selection. Moreover, minimally invasive diagnostics enhance the effectiveness of cancer treatment, reduce unnecessary side effects and lower healthcare costs. Additionally, the benefits offered by liquid biopsy products and their growing demand in the healthcare sector, specifically post-pandemic, have prompted stakeholders to implement advancements in non invasive diagnostics market that are likely to drive the liquid biopsy market growth in the forecast period. In May 2023, Guardant360 CDx from Guardant Health. Received approval in Singapore for use as companion diagnostic Tagrisso. Additionally, in July 2023, the Guardant360 CDx received reimbursement approval from the Japanese Ministry of Health, Labor and Welfare (MHLW).
Current Market Landscape of Liquid Biopsy Companies
The current market landscape features the presence of over 160 manufacturers offering more than 350 liquid biopsy products that are launched or under development for the diagnosis of various cancer indications. Overall, the liquid biopsy market seems to be well-fragmented, featuring the presence of very small, small, mid-sized, large, and very large companies having the required expertise to manufacture liquid biopsy products for different applications, such as early cancer detection, patient monitoring and treatment selection. It is worth mentioning that the majority of the manufacturers (60%) are based in North America. Notable examples of liquid biopsy companies based in the US include (in alphabetical order) ArcherDX, CellMax Life, ClearNote Health, DiaCarta, Personal Genome Diagnostics, Singlera Genomics, Sysmex Inostics and Helio Genomics.
Liquid Biopsy Market Trends Analysis: Increasing Partnerships and Collaborations to Foster Progress and Innovation
Stakeholders in the liquid biopsy industry have forged several partnerships in order to enhance their liquid biopsy product portfolio. The growing preference of patients towards non invasive cancer diagnostics over traditional painful tissue biopsy methods is evident from the rise in partnership activity. It is worth highlighting that more than 75% of deals were inked in the last three years. Notably, majority of the deals are focused on product / technology development agreements of liquid biopsies, followed by supply agreements. This can be attributed to the need for combining specialized technologies and expertise to create more accurate and comprehensive diagnostic solutions, as well as to expedite the development and commercialization of liquid biopsy products. These agreements allow companies to access complementary technologies, share resources, and capitalize the strengths to enhance the effectiveness of liquid biopsy products and meet the growing demand for advanced cancer detection and monitoring methods. In June 2023, Foundation Medicine signed an agreement with Merck KgaA to develop liquid biopsy companion diagnostic tests for select marketed and pipeline cancer therapies. In another deal inked between Naveris and Mayo Clinic in April 2023, the latter is evaluating NavDx liquid biopsy test in clinical trials for selection of patients with head and neck cancer caused by HPV.
Increase in Funding Reflects the Rising Interest in Minimally Invasive Cancer Diagnostics, which is likely to be Driven by Liquid Biopsy Market
The growing interest in liquid biopsy market can be validated by the fact that in the past four years, close to $7.3 billion has been invested by several investors based across the globe, in liquid biopsy companies. It is worth noting that, majority of the funds have been raised through venture rounds. In terms of the funding amount raised, we observed that Grail has raised the maximum funding amount ($1,214 million) through venture capital. In July 2023, MiRXES raised $50 million in series D venture funding for the development and commercialization of liquid biopsy products targeting colorectal cancer and the multi-cancer early detection test. In April 2023, Epic sciences raised $24 million in series G venture funding for liquid biopsy products targeting metastatic breast cancer.
Market Analysis: By Type of Circulating Biomarker, Circulating Tumor DNA Market Segment to Hold the Largest Share of the Liquid Biopsy Market
The global liquid biopsy market is estimated to be worth $4.01 billion in 2023. The market growth is expected to be driven by the rising prevalence of cancer, which leads to growing need for the development of non invasive cancer diagnostic products for early cancer diagnosis. In terms of application, majority of the liquid biopsy market share is anticipated to be captured by the products intended for clinical use. Further, in terms of type of circulating biomarkers, circulating tumor DNA is expected to capture the majority of the liquid biopsy market share during the forecast period.
Regional Analysis: North America and Europe Emerged as the Hubs of Liquid Biopsy Market; Asia-Pacific to Show the Fastest Market Growth
Majority of the liquid biopsy companies are headquartered in North America, followed by players based in Europe. ~40% share of the global liquid biopsy market is anticipated to be captured by players based in North America, by 2035. The factors responsible for the market growth of the liquid biopsy market in North America includes rising incidence of various cancer indications, increasing FDA approvals for novel liquid biopsy products and growing adoption of non invasive cancer diagnostics in the developed countries. The collaborative effort between research institutions and the healthcare industry underscores the promising future of liquid biopsy products.
Further, the Asia-Pacific market is showing positive signs of adoption of liquid biopsy tests. There have been some recent approvals in the Asian markets. Additionally, the liquid biopsy startups based in Asia-Pacific, such as Lucence Health have successfully raised funds to progress the development of liquid biopsy tests.
Key Liquid Biopsy Companies
Examples of key liquid biopsy companies engaged in liquid biopsy market (which have also been profiled in this market report; the complete list of companies is available in the full report) include, Amoy Diagnostics, ArcherDX, Biocartis, Cell Search, CellMax Life, Datar Cancer Genetics, , DiaCarta, EONE-DIAGNOMICS, Exosome Diagnostics, GeneCast Biotechnology, Integrated DNA Technologies, Lucence, MDNA Life Sciences, Miltenyi Biotec, NeoGenomics, ONCODE Scientific, OncoDNA, QIAGEN, PANAGENE, Personal Genome Diagnostics, Predicine, ScreenCell, Tecan and Thermo Fisher Scientific. The liquid biopsy market report includes an easily searchable excel database of all the liquid biopsy companies, worldwide.
Recent Developments in Liquid Biopsy Market
Several developments have taken place in the field of liquid biopsy, recently. Some of these recent initiatives have been mentioned below. These developments, even if they took place post the release of our market report, substantiate the overall market trends that we have outlined in our analysis.
- In June 2023, X-ZELL entered into agreement with MVZ for pathology , based in Germany for product / technology utilization agreement of cryoimmunostaining for the treatment of early stage prostate cancer.
- In May 2023, aiGENE has received a grant from Colorado Office of Economic Development and International Trade’s (OEDIT) for the development of liquid biopsy product used for patient monitoring and early cancer detection of multiple cancer indications.
The market report features an in-depth analysis, highlighting the capabilities of various companies engaged in liquid biopsy and other non invasive cancer diagnostics, across different segments, as defined below:
- A preface providing an introduction to the full market report, Liquid Biopsy Market, 2023-2035 (4th Edition).
- An outline of the systematic research methodology adopted to conduct the study on the liquid biopsy market and other non invasive cancer diagnostics, providing insights on the various assumptions, methodologies, and quality control measures employed to ensure accuracy and reliability of our findings.
- An overview of economic factors that impact the overall liquid biopsy market, including historical trends, currency fluctuation, foreign exchange impact, recession, and inflation measurement.
- An executive summary of the key insights captured during our research, offering a high-level view on the current state of the liquid biopsy market and its likely evolution in the short to mid-to-long term.
- A general overview of the cancer statistics and global burden of the disease, the importance of early cancer detection and cancer screening, highlighting details on different types of circulating biomarkers based on their function. It also features the emerging trends in intellectual property related to non invasive cancer diagnostics. Further, it provides information on the on the liquid biopsy cost and its benefits as well as challenges associated with non invasive cancer diagnostic.
- An overview on the need for non invasive cancer diagnostics and their importance; it also features different imaging techniques, screening assays and advanced approaches used for diagnosis of cancer along with their advantages and disadvantages.
- A detailed assessment of the overall market landscape of liquid biopsy products based on several relevant parameters, such as stage of development (launched and under development), type of product (assay kits, devices, software / algorithms and others), type of sample (blood / plasma and others), type of technique (next generation sequencing, polymerase chain reaction and others), type of circulating biomarker (cell free DNA, cell free RNA, circulating tumor DNA, extracellular vesicles and other circulating biomarkers), target disease indication (bladder cancer, breast cancer, colorectal cancer, gastric cancer, lung cancer, prostate cancer and others), application (early cancer detection, patient monitoring and treatment selection and others) and application area (clinical use and research use). Further, it also provides a list of players engaged in manufacturing liquid biopsy products, along with the information on their year of establishment, company size (based on number of employees), location of headquarters (region), location of headquarters (country), most active players (in terms of number of liquid biopsy products) most active players (in terms of number of liquid biopsy products).
- Tabulated profiles of prominent liquid biopsy companies (shortlisted based on product portfolio strength) manufacturing liquid biopsy products. Each profile features a brief overview of the company (including information on its year of establishment, number of employees, location of headquarters and leadership team), details related to its financial performance (if available), product portfolio, recent developments and an informed future outlook
- An analysis of the recent collaborations within the liquid biopsy market, based on several relevant parameters, such as year of partnership, type of partnership, type of partner, type of circulating biomarker, target disease indication, most active players (in terms of number of deals inked) and regional distribution of partnership activity that have taken place in this industry, during the period 2020-2023.
- A detailed analysis of funding and investments made in the liquid biopsy companies, during the period between 2016 and 2023, including instances of seed financing, venture capital, capital raised from IPOs, secondary offerings, grants / awards, other equity and debt financing. Further, these instances have been analyzed based on various relevant parameters, such as year of investment, amount invested, type of funding, type of circulating biomarker, target disease indication, application area, geography, most active players (in terms of number of funding instances and amount invested) and leading investors (in terms of number of funding instances).
- An insightful product competitiveness analysis of liquid biopsy products based on several relevant parameters, such as supplier strength (based on years of experience of the company), product competitiveness (based on type of product, stage of development, accreditation, availability of proprietary technology, availability of artificial intelligence, type of technique, type of sample, type of circulating biomarker, target disease indication, type of cancer, application and type of patient population) and company size (based on employee count of the product manufacturer).
- A detailed analysis of the initiatives of big pharma players, highlighting the key focus areas of such companies and analysis based on various relevant parameters, such as number of initiatives, type of initiative, stage of development, type of product, type of circulating biomarker, target disease indication, application and application area.
- A detailed analysis of the key acquisition targets, taking into consideration the historical trend of the acquisition activity of the players that have acquired other firms, since 2016. It offers a means for other industry stakeholders to identify potential acquisition targets.
- A detailed overview of the various non invasive diagnostic tests other than liquid biopsies, being manufactured by various companies for cancer screening and early detection.
- An in-depth analysis of the factors that can impact the growth of liquid biopsy market. It also features identification and analysis of key drivers, potential restraints, emerging opportunities, and existing challenges.
The key objective of this market report is to provide a detailed liquid biopsy market forecast analysis in order to estimate the existing market size and future opportunity for liquid biopsy companies over the next decade. Based on multiple parameters, likely adoption trends and through primary validations, we have provided an informed estimate on the market evolution during the forecast period 2023-2035. The market report also features the likely distribution of the current and forecasted opportunity within the liquid biopsy market across various segments, such as application (early cancer diagnosis, patient monitoring and recurrence monitoring), target disease indication (bladder cancer, breast cancer, colorectal cancer, gastric cancer, lung cancer, prostate cancer and others), type of circulating biomarker (cell free DNA, cell free RNA, circulating tumor DNA, extracellular vesicles and others circulating biomarkers), type of sample (blood / plasma and other analytes), end user (hospitals, research institutes and other end users) and key geographical regions (North America, Europe, Asia-Pacific and Rest of the World). In order to account for future uncertainties and to add robustness to our model, we have provided three liquid biopsy market forecast scenarios, namely conservative, base and optimistic scenarios, representing different tracks of the industry’s growth.
The opinions and insights presented in the market report were influenced by discussions held with stakeholders in the industry. For the purpose of the study, we invited stakeholders to participate in a survey to solicit their opinions on upcoming opportunities and challenges that must be considered for a more inclusive growth. The opinions and insights presented in this study were also influenced by discussions held with senior stakeholders in the industry. The report features detailed transcripts of interviews held with the following industry stakeholders:
- Director of a US based Mid-sized Organization
- Innovation Director of a Spain based Mid-sized Company
- Founder and Medical Director of an Australia based Small Company
- Founder and Chief Executive Officer of an India based Small Company
- Chief Executive Officer of an Australia based Small Company
- Chairman of the US based Small Company
- Founder, President and Chief Technology Officer of the US based Small Company
- Former Founder of the US based Small Company
- Former Chief Executive Officer and Co-founder of US based Small Company
- Former Chief Executive Officer of the US based Mid-sized Company
- Chief Operating Officer and Co-Founder of Canada based Small Company
- Chief Medical Officer of the US based Mid-sized Company
- Chief Scientific Officer of Sweden based Small Company
- Chief Scientific Officer of the US based Mid-sized Company
- Former Marketing Director of Belgium Mid-sized Company
- Former Sales and Marketing Manager of Italy based Small Company
- Former Strategic Technology Advisor of an Australia based Small Company
All actual figures have been sourced and analyzed from publicly available information forums and primary research discussions. Financial figures mentioned in this report are in USD, unless otherwise specified.
Table of Contents
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- 4basebio
- 4D Lifetec
- 50K Ventures
- 6 Dimensions Capital
- 8VC
- A&G Pharmaceutical
- Abbott
- AccessHope
- AccuraGen
- Ackermans & van Haaren
- Acobiom
- ACT Genomics
- Acuamark Diagnostics
- Agena Bioscience (acquired by Mesa Laboratories)
- Agendia
- Agilent Technologies
- aiGENE
- Alabama Capital Network
- Alexandria Venture Investments
- Alliance Global Group
- Alligator Bioscience
- Ally Bridge Group
- Amadix
- Amazon
- American Cancer Society
- Amgen
- Amoy Diagnostics (AmoyDx)
- Anchor Molecular
- ANGLE
- AnHeart Therapeutics
- Annoroad Gene Technology
- Anpac Bio-Medical Science
- Anthill Ventures
- Apostle
- Arboretum Ventures
- ARCH Venture Partners
- Archangel Investors
- ArcherDX
- ARNA Genomics
- Arquer Diagnostics
- Artiman Ventures
- ARUP Laboratories
- Arvinas
- Aspira Women's Health
- Astellas Pharma
- AstraZeneca
- Asuragen
- Aurum Ventures
- AWSensors
- BeAble Capital
- Beijing Fupu Daohe Investment Management
- Betta Pharmaceuticals
- Bezos Expeditions
- BGI Genomics
- Bill & Melinda Gates Foundation
- Bio-Rad
- BioCaptiva
- Biocartis
- Biocept
- BioChain
- Biodesix
- BioFluidica
- Biolidics (formerly known as Clearbridge BioMedics)
- Biological Dynamics
- Bioprognos
- BioReference Laboratories
- Biosplice Therapeutics
- BioVeda China Fund (BVCF)
- BioView
- BlackRock
- Blue Pool Capital
- BNO BIO
- Boehringer Ingelheim
- Boulder Ventures
- Brenden-Colson Center for Pancreatic Care
- BrightEdge
- Bristol Myers Squibb
- Bristol-Myers Squibb
- Broadway Angels
- BW Ventures
- C2i Genomics
- Cambridge Innovation Capital
- Canada Pension Plan Investment Board (CPP Investments)
- Canostix
- Capio Biosciences
- Capital Research and Management
- Caris Life Sciences
- Carrum Health
- Catalio Capital Management
- Cathay Fortune International
- CDBI Partners
- Celgene
- CellMax Life
- Cepheid
- China Merchants Securities International
- CIRCULOGENE
- ClearNote Health (Bluestar Genomics)
- Cleveland Clinic Lerner Research Institute
- Cleveland Diagnostics
- Clinical Genomics
- Cloudstone Venture Fund
- Co-win Healthcare Fund
- Co-Win Ventures
- Community Health Network
- ConcertAI
- Convergent Genomics
- CORE Diagnostics (acquired by Canopy Biosciences)
- CPH Capital
- CRF Investment
- Curta
- Cyclomics
- Datar Cancer Genetics
- Decheng Capital
- Delee
- Denlux Capital
- DermTech
- Detong Capital
- Devyser
- DiaCarta
- DiaDx
- Diagnolita
- Diatech Pharmacogenetics
- DSC Investment
- DT Capital
- Dxcover
- EarlyDx
- EDBI
- EDP Biotech
- eInfochips
- Eisai
- Eli Lilly
- Elicio Therapeutics
- Enterix
- EONE-Diagnomics Genome Center (EDGC)
- Epic Sciences
- Epigenomics
- Eurofins
- European Commission
- European Organisation for Research and Treatment of Cancer (EORTC)
- Exact Sciences
- ExBiome
- Exosome Diagnostics (acquired by Bio-Techne)
- Exosomics
- F-star
- Fairview Capital
- Farallon Capital
- Faro Capital
- FirstHealth
- Flare Therapeutics
- Flatiron Health
- Fluxion Biosciences
- Forestone Capital
- Formation 8
- Fortune Fountain Capital
- Fosun Pharmaceutical
- Foundation Medicine
- Fountain Medical Development
- Fox Chase Cancer Center
- Franklin Templeton Investments
- Freenome
- Fulgent Genetics
- Furong Investment
- FutureX Skyline Capital
- GeneCast Biotechnology
- GENinCode
- Genomic Testing Cooperative
- Genomictree
- Genostics
- GILUPI
- Glycanostics
- Good Health Capital
- GRAIL
- Green Pine Capital Partners
- Guardant Health
- Gunnar Nilsson Cancer Foundation
- Guojing Innovation Investment
- Gurnet Point Capital
- Hadean Ventures
- Hatteras Venture Partners
- HDFC
- Healthcor Partners Management
- HEDA Ventures
- Helio Genomics
- Helsinn Investment Fund
- HighLight Capital
- Hillhouse Capital Group
- Horizon
- HuangPu River (HPR) Capital
- Hummingbird Diagnostics
- Hyderabad Angels
- ICBC International
- Ikonisys
- Illumina
- Imperial Innovations
- Incyte
- Indian Angel Network
- Inivata
- Innovatus Capital Partners
- Inova Strategic Investments
- INOVIQ
- Institut Bergonié
- Institut Curie
- Institut Jules Bordet
- Intermountain Healthcare
- Interpace Biosciences (formerly known as Interpace Diagnostics)
- Inventures
- Invest4OncoDNA
- INVITEK Molecular
- IP Group
- iSelect Fund
- Istituto Diagnostico Varelli
- IVDiagnostics
- Janssen Pharmaceutical (acquired by Johnson & Johnson)
- Janus Henderson Investors
- Jennison Associates
- Johnson & Johnson
- Johnson & Johnson Innovation
- Jointown Pharmaceutical Group
- Junci Investment
- Junson Capital
- KEODES
- Kexin Capital
- Khosla Ventures
- Labcorp
- Laboratory for Advanced Medicine
- LeapFrog Investments
- Lexent Bio
- Lightspeed Venture Partners
- Lilly Asia Ventures
- Linden Capital Partners
- LiquidBiopsy.Center
- LLC
- Longwood Fund
- Loyal Valley Capital
- LU Holding
- Lucence
- Lung Cancer Research Foundation
- LungLife AI
- LYFE Capital
- MagBio Genomics
- Martell Diagnostic Laboratories
- Maryland Venture Fund
- Massachusetts General Hospital
- Matrix Partners China
- Mayo Clinic
- McKesson Ventures
- MD Anderson Cancer Center
- MDNA Life Sciences
- MDxHealth
- MedGenome
- Menarini Silicon Biosystems
- Merck
- Merck KGaA
- Mercy BioAnalytics
- Metabolomic Technologies
- MiCareo
- Micromedic Technologies (subsidiary of BioLight Life Sciences)
- Micronoma
- Miltenyi Biotec
- Minomic
- miR Scientific
- Mirati Therapeutics
- MiRXES
- Mitsui
- Molecular Stethoscope
- Multimmune
- Mumbai Angels
- myNEO
- Myriad Genetics
- Nan Fung Group
- Nanjing Kaiyuan Growth Capital Investments
- Nanostics
- NantHealth
- Natera
- National Cancer Center
- National Cancer Institute
- National Health Service (NHS)
- Naveris
- NeoGeneStar
- NeoGenomics
- NeoGenomics Laboratories
- New Enterprise Associates
- Nonacus
- North Carolina Biotechnology Center
- Northpond Ventures
- Novalis LifeSciences
- Novartis
- Novigenix
- Novo Holdings
- NRG Oncology
- nRichDX
- Nucleix
- NuView Life Sciences
- NVIGEN
- NYU Langone's Perlmutter Cancer Center
- Ochsner Health
- OCI Bio Investments
- Old College Capital
- Omnigen
- Oncimmune
- Oncode Institute
- Oncode Scientific
- OncoDNA
- OrbiMed
- OrbiMed Advisors
- OrbiMed Israel Partners
- Orebro University
- OSHU Knight Cancer Institute
- Pacific Edge
- PANAGENE
- Pangea Oncology
- Pantai Premier Pathology
- Paragon Genomics
- Parampara Fund
- Parker Institute for Cancer Immunotherapy
- PBM Capital
- Perceptive Advisors
- PeriRx
- Personal Genome Diagnostics
- Personalis
- Pfizer
- PFM Health Sciences
- Pillar Biosciences
- pluriSelect Life Science
- Point32Health
- Polymer Char
- Positive Bioscience
- Precise Medical Supplies
- Precision for Medicine
- Precision Pathology Services
- Predicine
- Premier
- Princess Margaret Cancer Centre
- Promega
- Prosperico Venture
- Provista Diagnostics
- Proxima Ventures
- PT ELION
- Q2 Solutions
- QIAGEN
- Quest Diagnostics
- Qure
- R-Cubed Capital
- RA Capital
- RA Capital Management
- Radiomics
- Radius Health
- RainDance Technologies
- Rarecells
- Resolution Bioscience
- Resolution Bioscience (acquired by Agilent Technologies)
- RGCC Group
- Roche
- Roche Diagnostics
- Rock Springs Capital
- Rongsheng Investment
- RT Ventures
- RUBYnanomed
- Rutherford Regional Health System
- SAGA Diagnostics
- Saha Fund
- Sambrinvest
- Sands Capital
- Sangel Capital
- Sansure Biotec
- Saphetor
- Savicell Diagnostics
- Science 37
- Scottish Enterprise
- ScreenCell
- Sebela Pharmaceuticals
- Segulah Medical Acceleration (SMA)
- SensID
- Sequoia Capital
- Sequoia Capital China
- Sequoia Capital India
- Servier
- Shandong Huamei Biotechnology
- Shandong Lukang Pharmaceutical
- Shanghai Fosun Long March Medical Science
- SIMFO
- Singlera Genomics
- Sky Ventures
- Société Régionale d'Investissement de Wallonie (SRIW)
- Sofina
- Sofinim
- Sofinnova Ventures
- SoftBank Ventures
- Soleus Capital
- Sozo Ventures
- SPD Scientific
- StageZero Life Sciences
- StartX
- STEMCELL Technologies
- Sutter Hill Ventures
- Swedish Governmental Agency for Innovation Systems
- Swelife
- Swift Biosciences (acquired by IDT)
- SYMBIOSIS
- Sysmex Inostics (Subsidiary of Sysmex)
- T Rowe Price Associates
- Takara Bio
- Takeda Pharmaceuticals
- Tecan
- Tempus
- Tesis Biosciences
- The Heritage Group
- The Ohio State University Comprehensive Cancer Center
- The Royal Marsden NHS Foundation Trust
- Theranosis Life Sciences (acquired by ONCOPHENOMICS)
- Thermo Fisher Scientific
- Todos Medical
- Tymora Analytical Operations
- U.S. Department of Veterans Affairs
- Universal Diagnostics
- University College London
- University Medical Center Utrecht
- USC Michelson Center for Convergent Bioscience
- VA Palo Alto Health Care System (VAPAHCS)
- Vall d'Hebron Institute of Oncology (VHIO)
- Virtus Health
- VolitionRx
- Vortex Biosciences
- Waseda University
- West Cancer Center
- Windham Venture Partners
- Wisemont Capital
- WntResearch
- Woodford Patient Capital Trust
- WRF Capital
- WS Investment
- WuXi NextCODE
- X-ZELL
- XboXLab
- Yahui Precision Medical Fund
- Yale School of Medicine
- Yemaachi Biotech
- Yi Fang Group
- Yifuze Equity Investment Fund
- Zehou Capital
- ZERO Prostate Cancer
- Zinexts Life Science
- Zodius
- Zogen Genética Molecular
Methodology
LOADING...
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 331 |
| Published | December 2023 |
| Forecast Period | 2023 - 2035 |
| Estimated Market Value ( USD | $ 5.4 Billion |
| Forecasted Market Value ( USD | $ 29.5 Billion |
| Compound Annual Growth Rate | 15.2% |
| Regions Covered | Global |
